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Abstract
Background: It has been suggested that circulating fibrocytes and endothelial cells actively participate in the
intense remodelling of the pulmonary vasculature in patients with idiopathic pulmonary fibrosis (IPF). Indeed,
fibrotic areas exist that have fewer blood vessels, whereas adjacent non-fibrotic tissue is highly vascularized. The
number of circulating endothelial cells (CEC) and endothelial progenitor cells (EPC) might reflect the balance
between vascular injury and repair. Thus, fibrocytes as well as endothelial cells could potentially be used as
biomarkers of disease progression and treatment outcome.
Methods: Peripheral blood samples were collected from 67 patients with a multidisciplinary diagnosis of IPF and
from 45 age-matched and sex-matched healthy volunteers. Buffy coat was isolated according to standard
procedures and at least 20 million cells were stained with different monoclonal antibodies for the detection
of CEC, EPC and circulating fibrocytes. For the detection of CEC and EPC, cells were stained with anti-CD45,
anti-CD34, anti-CD133, anti-CD14, anti-CD309 and with the viability probe Far-Red LIVE/DEAD. For the
detection of circulating fibrocytes, cells were first stained with LIVE/DEAD and the following monoclonal
antibodies: anti-CD3, anti-CD19, anti-CD45, anti-CD34 and anti-CD14, then cells were fixed, permeabilized and stained
with fluorochrome-conjugated anti-collagen I monoclonal antibodies.
Results: Patients with IPF displayed almost undetectable levels of circulating fibrocytes, low levels of CEC, and normal
levels of EPC. Patients treated with nintedanib displayed higher levels of CEC, but lower levels of endothelial cells
expressing CD309 (the type II receptor for vascular endothelial growth factor). Treatment with both nintedanib and
pirfenidone reduced the percentage of CEC and circulating fibrocytes.
Conclusions: Levels of CEC were reduced in patients with IPF as compared to healthy individuals. The anti-fibrotic
treatments nintedanib and pirfenidone further reduced CEC levels. These findings might help explain the mechanism
of action of these drugs and should be explored as predictive biomarkers in IPF.
Keywords: Circulating fibrocytes, Endothelial cells, Idiopathic pulmonary fibrosis, Nintedanib, Pirfenidone
* Correspondence: andrea.cossarizza@unimore.it
†Equal contributors
1Department of Surgery, Medicine, Dentistry and Morphological Sciences,
University of Modena and Reggio Emilia School of Medicine, via Campi,
287-41125, Modena, Italy
8Dipartimento Sperimentale Interaziendale, Campus San Lazzaro, University
of Modena and Reggio Emilia, 42122 Reggio Emilia, Italy
Full list of author information is available at the end of the article
© 2015 De Biasi et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
De Biasi et al. BMC Medicine  (2015) 13:277 
DOI 10.1186/s12916-015-0515-0
Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive, irreversible and ultimately lethal lung disease of
unknown cause and unclear pathogenic mechanisms,
characterized by myofibroblast accumulation and lung
scarring [1, 2]. At present, there are no reliable clinical
parameters or non-invasive biomarkers predicting the
clinical course of IPF [3]. A growing body of evidence
indicates that the disease can result from the abnormal
behaviour of the alveolar epithelial cells, which provokes
the migration, proliferation and activation of mesenchy-
mal cells. This results in the formation of fibroblast and
myofibroblast foci secreting exaggerated amounts of
extracellular matrix molecules, with the subsequent
destruction of the lung architecture [4]. It has been hy-
pothesized that an extra-pulmonary source of fibroblast/
myofibroblasts exists, which likely has a bone marrow
origin and can be detected in the blood [5].
In 1994, using state-of-the-art techniques, circulating
fibrocytes were identified as cells that exit the blood
stream, migrate into wounds and contribute to wound
repair [6]. Fibrocytes are spindle-shaped, bone marrow-
derived mesenchymal progenitor cells that co-express a
variety of cell surface markers related to leukocytes,
hematopoietic progenitor cells and fibroblasts. They
express a variety of mesenchymal markers, including
collagen I, as well as the common leukocyte marker
CD45 and the hematopoietic stem cell marker CD34.
They do not express T cell markers (CD3, CD4 and
CD8), B cell markers (CD19) or myeloid markers
(CD14) [7]. It has been shown that, in healthy donors,
they can represent up to 1 % of circulating nucleated
cells [8–11] and can express chemokine receptors such
as CXCR4 and CCR7; they have been found in a variety
of tissues under both physiological and pathological
states [9, 12]. However, scanty data exist on the fine
characterization of these circulating cells, whose relative
rarity in blood obviously represents an obstacle to their
precise analysis.
The biological axis CXCL12/CXCR4 could be involved
in mediating the contribution of fibrocytes to pulmonary
fibrosis [10]. Indeed, the high expression of CXCL12 in
lung injury creates a chemokine gradient for CXCR4+
fibrocytes, which can be released from the bone marrow
and recruited to the lungs [13]. Once they extravasate
and enter the target tissue, fibrocytes can differentiate
into fibroblasts and myofibroblasts [14]. So, it has been
supposed that circulating fibrocytes might contribute to
the intense remodelling of the pulmonary vasculature in
patients with IPF, or at least represent a biomarker of
disease activity [15].
Multiple mechanisms play a role in IPF pathogenesis,
including abnormal vascular repair and remodelling [16].
During IPF, fibrogenesis is strongly associated with
abnormal vascular remodelling [17]. Indeed, there is a
body of evidence suggesting that the impairment of re-
endothelization mechanisms after alveolar injury may
lead to the destruction of lung architecture, and conse-
quently trigger fibrosis [18]. Failure of re-endothelization
may induce loss of the alveolar-capillary integrity, which
might be the point after which fibrosis becomes inevit-
able [16]. Fibrotic areas have few blood vessels, whereas
adjacent non-fibrotic tissue is highly vascularized [19].
There are almost no capillaries within the fibroblastic
foci, indicating that the fibrotic process in IPF does not
need neovascularization [20]. In this regard, it has been
suggested that the respective abundance of circulating
endothelial cells (CEC) and endothelial progenitor cells
(EPC) might reflect the balance between vascular
injury/repair and potentially serve as biomarkers of the
disease [17]. Few data on CEC or EPC exist from pa-
tients with IPF.
With the aim of clarifying whether CEC and their
precursors and circulating fibrocytes are altered in
IPF, and to understand whether these cells may be
used as biomarkers, we studied such cells in a cohort
of Italian patients with IPF, some of whom were lon-
gitudinally followed. We used an innovative methodo-
logical approach, based upon sophisticated techniques
that employ acoustic, multiparametric flow cytometry
that allows a precise and fine analysis of these rare
cell types.
Methods
Patients
All incident and prevalent patients with IPF from six
Italian centres (Modena, Reggio Emilia, Bologna, Siena,
Napoli and Catania) were deemed eligible for this
study. All patients fulfilled 2011 American Thoracic
Society/European Respiratory Society/Japanese Respiratory
Society/Latin American Thoracic Association guideline
diagnostic criteria [21]. Complete medical history and lung
function tests were acquired at enrolment. Six-month
follow-up visits and lung function tests were scheduled for
up to 2 years. Blood samples for the analysis of circulating
fibrocytes and endothelial cells were obtained at enrolment
and during follow-up visits.
The study has been approved by the Local Ethical
Committee (Modena, Number of practice 31/12), and
written informed consent was obtained from each
patient.
Among the patients with IPF, 18 were treated with
pirfenidone, 13 with nintedanib, and 26 were untreated.
Patient characteristics are reported in Table 1.
Blood collection and cell analysis
Thirty millilitres of blood were collected through a ven-
ous drawing in EDTA tubes. The first 3 mL of blood
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from the venipuncture were not used for cell analysis,
because of the contaminating presence of endothelial
cells derived from the vessel wall. Buffy coat was then
prepared according to standard procedures, and cells were
stained with different monoclonal antibodies (mAbs) for
the detection of CEC, EPC and circulating fibrocytes. For
the detection of CEC and EPC a minimum of 10 millions
cells were stained with anti-CD45 PE (eBioscience, San
Diego, CA, USA), anti-CD34 PC7 (Beckman Coulter,
Hieleah, FL, USA), anti-CD133 APC (Miltenyi GmbH,
Bergisch Gladbach, Germany), anti-CD14 APC-VIO770
(Miltenyi), anti-CD309 FITC (R&D Systems, Minneapolis,
MN, USA) and viability probe Far-Red LIVE/DEAD.
Table 1 Patients’ characteristics
Number Percentage Median IQR
Gender
Male 53
Female 14
Age (years) 74 68.5–77.0
Time from diagnosis (years) 3 2.0–4.5
Smoking history
Non smoker 19
Smoker or former smoker 41
Forced vital capacity
(% predicted)
75.0 56.75–93.0
DLCO (% predicted) 41.0 34.0–60.0
GAP stage (%)
I 32.70
II 53.10
III 14.30
Treatment
Pirfenidone 18
Nintedanib 13
Untreated 26
DLCO Diffusing capacity of the lungs for CO2, GAP Gender, Age and Physiology
Index, IQR interquartile range
Table 2 Table summarizing the excitation sources and
fluorescence emissions used for the detection of circulating
endothelial cells and their precursors
Monoclonal antibody
(mouse anti-human)
Directly conjugated
fluorochrome
Excitation/emission
(nm)
Anti-CD34 PC7 488/750
Anti-CD45 PE 488/530
Anti-CD133 APC 637/660
Anti-CD309 FITC 488/519
Anti-CD14 APCVio770 637/785
LIVE/DEAD Far Red 637/>665
Table 3 Table summarizing the excitation sources and
fluorescence emission used for the detection of circulating
fibrocytes
Monoclonal antibody
(mouse anti-human)
Directly conjugated
fluorochrome
Excitation/emission
(nm)
Anti-CD34 PC7 488/750
Anti-CD45 PE 488/530
Anti-CXCR4 APC 637/660
Anti-collagen I FITC 488/519
Anti-CD19 PE-Cy5.5 488/690
Anti-CD3 PE-Cy5.5 488/690
Anti-CD14 APCVio770 637/785
LIVE/DEAD Red Fixable 488/615
Fig. 1 Gating strategy for the identification of circulating endothelial
cells (CEC) and endothelial progenitor cells (EPC). Debris, monocytes
and dead cells were excluded by the use of an electronic gate and
the dump channel, containing cells identified by mAbs against CD14
and a viability marker, i.e. LIVE/DEAD. CEC and EPC were identified
on the basis of the expression of CD34, CD45 and CD133: CEC were
defined as CD45dim, CD34+ and CD133− while EPC were defined as
CD45−, CD34+ and CD133+. The expression of CD309 (VEGFR-2,
KDR) was detected among EPC and CEC. FSC forward scatter, SSC
side scatter
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For the detection of circulating fibrocytes a minimum
of 20 million cells were stained with Red Fixable LIVE/
DEAD probe (Thermo Fisher,Eugene, OR, USA ) and
the following surface mAbs: anti-CD3 PE-CY 5.5 (Bec-
ton Dickinson, San José, CA, USA), anti-CD19 PE-CY
5.5 (Becton Dickinson), anti-CD45 PE (eBioscience),
anti-CD34 PC7 (Beckman Coulter), anti-CD14 APC-
VIO770 (Miltenyi) and anti-CXCR4 APC (Becton Dick-
inson). Cells were fixed and permeabilized using Cytofix/
Cytoperm buffer set (Becton Dickinson) and stained with
directly conjugated mAb anti-collagen I FITC (Merck
Millipore, Billerica, MA, USA). Tables 2 and 3 report the
mAbs used and the relative fluorochromes.
Acquisition of samples
For phenotype analysis, cells were acquired using a 14-
colour 4-laser high-speed Attune NxT flow cytometer
(Thermo Fisher). Single staining and fluorescence minus
one (FMO) controls were performed for all panels to set
proper compensation and define positive signals [22]. In
order to identify rare cells like human peripheral CEC,
EPC or circulating fibrocytes, it was mandatory to ac-
quire a huge number of cells [23], that is, of the order of
several million per sample. Thus, for the phenotypic
analysis, we used a novel acoustic flow cytometer able to
align cells in the flow chamber using ultrasound, acquir-
ing up to 35,000 cells per second. This was crucial to ob-
tain the number of cells required for a correct statistical
analysis, which was typically >10 million. Starting from a
buffy coat, we were therefore able to clearly identify
CEC, EPC or fibrocytes among peripheral blood cells.
Statistical analyses
Data were analysed by FlowJo 9.8.5 and GraphPad 6.0
software, using the Wilcoxon T test and non-parametric
analysis of variance test (Kruskal–Wallis test).
Results and discussion
Detection of fibrocytes, CEC and EPC requires the analysis
of a large number of cells
The cytometric approach that we used in this investiga-
tion was different from that of previous studies, which,
Fig. 2 Gating strategy for the identification of circulating collagen I+ cells, i.e. fibrocytes. Debris, B cells, monocytes and dead cells were removed
by an electronic gate as described in the legend to Fig. 1. Circulating fibrocytes were identified as CD34+, CD45+ and collagen I+. The expression
of CXCR4 was then evaluated among circulating fibrocytes. Lower panels, referred to cultured human fibroblasts, represents a positive control of
collagen I staining (>95 % cells were positive). FSC forward scatter, SSC side scatter
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mainly for technical reasons, could only analyse a rela-
tively low number of events. The high number of cells
that we could acquire and analyse, along with the use of
Poisson statistics, allowed a correct interpretation of the
data [23]. As shown in Fig. 1, which reports a represen-
tative analysis of CEC and EPC, cells were first selected
according to physical parameters; debris and aggregates
were then removed according to the forward scatter
(FSC)-A versus FSC-H dot plot. In this population, dead
cells and monocytes were removed using a ‘dump’ chan-
nel. The parameter ‘time’ shown in the middle upper
panel was used to monitor the stability of the flow cyto-
metric high-speed acquisition of events. CEC and EPC
were identified on the basis of the expression of CD34,
CD45 and CD133: CEC were defined as CD45dim,
CD34+ and CD133− while EPC were defined as CD45−,
CD34+ and CD133+ [24]. The parental population was
represented by peripheral blood mononuclear cells that
were alive (i.e. negative to LIVE/DEAD staining) and
negative for CD14. Expression of CD309 (i.e. the type II
receptor for the vascular endothelial growth factor,
VEGFR-2, also named KDR) was detected among EPC
and CEC.
The gating strategy used for the identification of cir-
culating fibrocytes involved the exclusion of aggregates
(by using an FSC-A versus FSH-H dot plot). In this
population, T lymphocytes, B lymphocytes and dead
cells were excluded. In this pure population, circulat-
ing fibrocytes were defined as CD34+, CD45+ and
collagen I+ cells (Fig. 2). The FMO approach was also
used to detect positive cells. Moreover, we could
search for the presence of CXCR4 circulating fibro-
cytes (see below).
Low levels of circulating fibrocytes in patients with
idiopathic pulmonary fibrosis
By using a sophisticated multiparametric analysis on a
very sensitive flow cytometer, we could study and pre-
cisely quantify the presence of fibrocytes in patients with
IPF. It is of note that, in order to avoid a possible unspe-
cific staining due to a secondary antibody, we used a dir-
ectly conjugated mAb recognizing collagen I and freshly
isolated peripheral blood cells (Fig. 2).
In patients with IPF, the proportion of fibrocytes was
below 1 % in almost all samples (see a representative
example in Fig. 2, middle right panel). This was also
the case in healthy controls (not shown). This result
is in contrast with previous studies performed on
freeze-thawed, fixed, permeabilized peripheral blood,
which claim that the percentage of fibrocytes in acute
Fig. 3 Percentages of circulating endothelial cells (CEC) and endothelial progenitor cells (EPC) in patients with idiopathic pulmonary fibrosis (IPF)
and healthy participants. Scatter plots and median (line) indicating (a) the percentages of CEC; (b) the amount of CD309 among CEC; (c) the
percentage of EPC; (d) the amount of CD309 among EPC in healthy donors (CTR) and patients (IPF). P-values, calculated using a Mann–Whitney
test, are indicated in the figure
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IPF can be as high as 20 % [25]. This observation has
been argued by others, because samples were not op-
timally used [26], and the number of events was likely
too low to reach statistical significance. Moreover, no
functional analysis have been performed on purified
populations of fibrocytes isolated from blood to dem-
onstrate their lineage. In our study, we have not
confirmed the previously reported high levels of fibro-
cytes in blood from patients with IPF. Moreover, be-
cause it is almost impossible to sort and perform
functional analysis of such cells (i.e., cells that are not
viable, because their cytometric identification through
the identification of collagen I requires permeabilization
of plasma membrane and cell fixation), further studies
are needed to clarify the meaning of collagen I+ cells,
which are at present defined as fibrocytes, in periph-
eral blood.
Patients with idiopathic pulmonary fibrosis displayed low
levels of circulating endothelial cells
Patients with IPF displayed low levels of CEC (Fig. 3a),
along with a significantly lower amount of CEC express-
ing CD309 (Fig. 3b), as compared to controls. They also
displayed a slightly higher percentage of EPC (Fig. 3c),
which, however displayed a lower expression of CD309
(Fig. 3c) than those of healthy participants. It is note-
worthy that six out of seven of the patients with the
highest levels of EPC were untreated.
Fig. 4 Percentages of circulating endothelial cells (CEC), endothelial progenitor cells (EPC) and circulating fibrocytes in patients with idiopathic
pulmonary fibrosis treated with different therapies. Bar plots with error bars (mean + standard error of the mean) indicating (a) the percentage of
CEC; (b) the amount of CD309 among CEC; (c) the percentage of EPC; (d) the percentage of EPC expressing CD309; (e) circulating collagen I+ cells;
(f) the amount of CXCR4 among fibrocytes in untreated patients (UNTR) and in patients treated with pirfenidone (PIR) or nintedanib (NIN). P-values,
calculated using a Kruskal–Wallis test, only significant values are displayed
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The decrease in CD309 expression could be due to dif-
ferent factors, ranging from the progression of the dis-
ease per se in untreated patients to the pharmacological
effect of pirfenidone and nintedanib, which can decrease
the expression of CD309/VEGF-R, altering the VEGF–
VEGFR axis [27]. For instance, nintedanib binds to the
intracellular ATP-binding pocket of fibroblast growth
factor (FGF) receptors, platelet-derived growth factor
(PDGF) receptors and VEGFRs, blocking the autophos-
phorylation of these receptors and the downstream sig-
nalling cascades (reviewed in [28]). Alternatively, it
could be hypothesized that CEC are able to home into
injured tissue to participate in lung re-endothelization,
and this phenomenon diminishes their number in per-
ipheral blood.
Patients with idiopathic pulmonary fibrosis treated with
nintedanib have a higher level of circulating endothelial
cells, but a lower number of endothelial cells expressing
CD309
We then compared the levels of endothelial cell popula-
tions and collagen I+ cells in untreated and treated pa-
tients with IPF. Untreated patients displayed lower levels
of CEC than patients treated with nintedanib or pirfeni-
done (Fig. 4a); treated patients also displayed lower
levels of CEC expressing CD309 (Fig. 4b). Among these
three groups of patients with IPF, we did not find statis-
tically significant differences in EPC population (Fig. 4c),
although the percentage of EPC expressing CD309 was
lower in patients treated with nintedanib (Fig. 4d). The
percentage of circulating collagen I+ cells, defined as
Fig. 5 Changes in the percentages of circulating endothelial cells (CEC), endothelial progenitor cells (EPC) and circulating fibrocytes in all treated
patients with idiopathic pulmonary fibrosis after 6 months of treatment. Before-and-after graphs indicate the trends of different cell populations:
(a) the percentages of CEC; (b) the amount of CD309 among CEC; (c) the percentage of EPC; (d) the amount of CD309 among EPC; (e) circulating
collagen I+ cells; and (f) the amount of CXCR4 among fibrocytes. P-values, calculated using a Wilcoxon test for paired data, only significant values
are displayed
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fibrocytes (Fig. 4e), and of fibrocytes expressing CXCR4
(Fig. 4f ) was similar between untreated and treated
patients.
Nintedanib and pirfenidone reduce the percentage of
circulating endothelial cells and circulating fibrocytes
(collagen I+ cells) after 6 months of treatment
We analysed the percentage and the phenotype of CEC,
EPC and circulating fibrocytes in 12 patients before and
after 6 months of anti-fibrotic treatment. It has to be
underlined that the detection and quantification of cir-
culating fibrocytes, that is, cells that express collagen I,
is quite problematic for several reasons, starting with
their extremely low number. Furthermore, to be
extremely rigorous, we cannot exclude the possibility
that some CD14+ cells that express CD34 (or that just
bind unspecifically to the anti-CD34 mAb by Fc recep-
tors) could express collagen I, and thus this population
could become an artefact of the analysis. In any case,
given that this hypothesis is quite unlikely and we per-
formed all possible quality control measures, we clearly
show that collagen I+ cells decrease significantly after
therapy.
The percentages of CEC and CEC expressing CD309
were significantly decreased after 6 months of treatment
(Fig. 5a, b). After 6 months, patients with IPF displayed no
differences in the percentage of EPC (Fig. 5c), nor in the
percentage of EPC expressing CD309 (Fig. 5d). Moreover,
Fig. 6 Changes in the percentages of circulating endothelial cells (CEC), endothelial progenitor cells (EPC) and circulating fibrocytes in patients with
idiopathic pulmonary fibrosis treated with nintedanib after 6 months of treatment. Before-and-after graphs indicate the trend of different cell populations:
(a) the percentages of CEC; (b) the amount of CD309 among CEC; (c) the percentage of EPC; (d) the amount of CD309 among EPC; (e) circulating
collagen I+ cells; (f) the amount of CXCR4 among fibrocytes. P-values, calculated using a Wilcoxon test for paired data, only significant values are
displayed
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after 6 months of nintedanib and pirfenidone treatments,
circulating fibrocytes were nearly undetectable in most pa-
tients (Fig. 5e), and circulating fibrocytes expressing
CXCR4 showed a significant decrease (Fig. 5f). Likely be-
cause of the relatively low number of patients we were
able to analyse, we could not find any correlation between
CEC or CD309 expression, or with any clinical parameter
(data not shown).
Treating patients with IPF is a major medical problem
[29]. Pirfenidone attenuated the fibrocyte pool size in
bleomycin-treated mouse lungs via attenuation of CCL2
and CCL12 production in vivo, and fibrocyte migration
was inhibited by pirfenidone in vitro [30]. Inhibition of
these cells is considered a mechanism of the anti-fibrotic
action of the drug [30], and indeed pirfenidone first
showed clinical amelioration in patients with IPF [31].
Recently, nintedanib has shown beneficial effects in
patients with IPF (clinical trials TOMORROW, INPULSIS
1 and INPULSIS 2) [32, 33]. Nintedanib was originally
developed as an angiostatic factor for cancer treatments,
and was approved to treat patients with lung cancer with
advanced adenocarcinoma after first-line chemotherapy.
Inhibition by nintedanib ultimately results in the re-
duced proliferation, migration and survival of fibroblasts,
and potentially attenuates angiogenesis in the lung
[34, 35]. Nintedanib has shown consistent anti-fibrotic
and anti-inflammatory activities in bleomycin-induced
pulmonary fibrosis in rodents [28, 36] and in human
fibroblasts isolated from the lungs of patients with
IPF, and inhibits FGF-induced, PDGF-induced, VEGF-
induced profibrotic effects in human lung fibroblasts
from patients with IPF [36–39]. Accordingly, in eight
patients taking nintedanib, we found significant changes
in CEC levels and in numbers of CEC expressing CD309,
as well as in collagen I+ cells (Fig. 6). The number of pa-
tients being treated with pirfenidone was too low to allow
any statistical analysis, although a similar trend was found
concerning CD309 expression (data not shown).
Conclusions
This multicentric study is the first to provide cross-
sectional and longitudinal analyses of CEC and fibro-
cytes amongst Italian patients with IPF. Our study was
performed on blood samples—we could not analyse lung
tissue from patients with IPF. Indeed, the most critical
obstacle to translating information obtained from mo-
lecular or cellular in vitro or ex vivo studies into clinical
applications is the scarcity of lung tissue, especially in
the context of a rare disease. Although some patients
undergo biopsy, in most cases either lung biopsy is not
indicated, or the risk associated with the procedure pre-
cludes it from being performed. Given the fact that
fibrocytes might be correlated with endothelial cells dur-
ing the remodelling process of fibrotic tissue, and given
that drugs used in IPF may modulate the function of
CEC, the aim of this study was to understand whether
more accessible cells like circulating fibrocytes and
endothelial cells may be used as surrogate biomarkers of
disease outcome in patients with IPF treated with differ-
ent drugs.
First, we investigated the phenotype of CEC and EPC
and found a significant decrease in the expression of
CD309 among endothelial cell populations. Thus, it is
likely that the identification of such a subpopulation
could be of clinical relevance. Second, we investigated
the percentage of circulating collagen I+ cells, defined as
fibrocytes, in patients with IPF treated with different
therapies, and we found that there was no difference
compared with healthy controls. The change in the ex-
pression of CXCR4 in such cells after 6 months of ther-
apy could be indicative of a therapeutic effect, in terms
of diminished homing to the lung. However, because of
the relatively small number of patients we could analyse,
further data are needed to clarify this aspect.
This study had some other limitations. First, we were
not able to follow up the entire IPF cohort. We also could
not clarify the molecular mechanism(s) by which circulat-
ing cells expressing collagen I and endothelial cells co-
operate to form fibrotic foci. However, it could be
hypothesized that CEC sustain the vascularization around
the fibrotic foci, and thus play a pathogenic role. In con-
clusion, although further studies are needed to confirm
that CEC and fibrocytes may be used as surrogate bio-
markers of disease presence, severity, rate of progression
and treatment outcome, the change in CD309 expression
in endothelial cells suggests that such receptors could
likely become a new target for therapies against IPF.
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